In this study, the type of amyloidosis (AL vs. ATTR amyloidosis), renal function and tolerability of ACE-inhibitor therapy were associated with a better global and cardiac outcome in the contemporary cohort (Table 2). The gene discussed is ACE; the disease is axial length measurement.